340B Report Conclusions Valid Despite Underlying Data Problems, IG Says
This article was originally published in The Pink Sheet Daily
Executive Summary
HHS Office of Inspector General withdraws its report on 340B drug pricing because of incorrect data mistakenly supplied by CMS. OIG plans to conduct a wider review of the 340B program before reissuing the report.
You may also be interested in...
Hospitals Eligible For Discounted Drugs Would Increase Under Legislation
A bill being drafted by the Senate Republican leadership would facilitate hospital participation in the federal Sec. 340B drug discount program through model contracts and relaxation of inventory management requirements, Public Hospital Pharmacy Coalition General Counsel von Oehsen says.
Hospitals Eligible For Discounted Drugs Would Increase Under Legislation
A bill being drafted by the Senate Republican leadership would facilitate hospital participation in the federal Sec. 340B drug discount program through model contracts and relaxation of inventory management requirements, Public Hospital Pharmacy Coalition General Counsel von Oehsen says.
340B Drug Pricing Data Should Be Listed On Secure Website, IG Recommends
The HHS Inspector General estimates that 340B entities paid an additional $41.1 mil. on outpatient drugs in September 2002 because they could not verify the ceiling price. HRSA has begun updating contact information and 340B participation status in real-time.